Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강덕희 | * |
dc.contributor.author | 최규복 | * |
dc.contributor.author | 김승정 | * |
dc.contributor.author | 류동열 | * |
dc.contributor.author | 유민아 | * |
dc.date.accessioned | 2016-08-29T12:08:51Z | - |
dc.date.available | 2016-08-29T12:08:51Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 0513-5796 | * |
dc.identifier.other | OAK-18703 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/231592 | - |
dc.description.abstract | Purpose: Endothelial dysfunction (ED) is a pivotal phenomenon in the development of cardiovascular disease (CVD) in patients receiving hemodialysis (HD). Indoxyl sulfate (IS) is a known uremic toxin that induces ED in patients with chronic kidney disease. The aim of this study was to investigate whether AST-120, an absorbent of IS, improves microvascular or macrovascular ED in HD patients. Materials and Methods: We conducted a prospective, case-controlled trial. Fourteen patients each were enrolled in respective AST-120 and control groups. The subjects in the AST-120 group were treated with AST-120 (6 g/day) for 6 months. Microvascular function was assessed by laser Doppler flowmetry using iontophoresis of acetylcholine (Ach) and sodium nitroprusside (SNP) at baseline and again at 3 and 6 months. Carotid arterial intima-media thickness (cIMT) and flow-mediated vasodilation were measured at baseline and 6 months. The Wilcoxon rank test was used to compare values before and after AST-120 treatment. Results: Ach-induced iontophoresis (endothelium-dependent response) was dramatically ameliorated at 3 months and 6 months in the AST-120 group. SNP-induced response showed delayed improvement only at 6 months in the AST-120 group. The IS level was decreased at 3 months in the AST-120 group, but remained stable thereafter. cIMT was significantly reduced after AST-120 treatment. No significant complications in patients taking AST-120 were reported. Conclusion: AST-120 ameliorated microvascular ED and cIMT in HD patients. A randomized study including a larger population will be required to establish a definitive role of AST-120 as a preventive medication for CVD in HD patients. © Yonsei University College of Medicine 2016. | * |
dc.language | English | * |
dc.publisher | Yonsei University College of Medicine | * |
dc.subject | AST-120 | * |
dc.subject | Endothelial dysfunction | * |
dc.subject | Hemodialysis | * |
dc.subject | Indoxyl sulfate | * |
dc.subject | Laser-Doppler flowmetry | * |
dc.subject | Microvascular circulation | * |
dc.title | AST-120 improves microvascular endothelial dysfunction in end-stage renal disease patients receiving hemodialysis | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 57 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 942 | * |
dc.relation.lastpage | 949 | * |
dc.relation.journaltitle | Yonsei Medical Journal | * |
dc.identifier.doi | 10.3349/ymj.2016.57.4.942 | * |
dc.identifier.wosid | WOS:000376162500019 | * |
dc.identifier.scopusid | 2-s2.0-84969203982 | * |
dc.author.google | Ryu J.-H. | * |
dc.author.google | Yu M. | * |
dc.author.google | Lee S. | * |
dc.author.google | Ryu D.-R. | * |
dc.author.google | Kim S.-J. | * |
dc.author.google | Kang D.-H. | * |
dc.author.google | Choi K.B. | * |
dc.contributor.scopusid | 강덕희(17233695600) | * |
dc.contributor.scopusid | 최규복(36096388100) | * |
dc.contributor.scopusid | 김승정(8619054500) | * |
dc.contributor.scopusid | 류동열(7103144218;56997547400;56669926200) | * |
dc.contributor.scopusid | 유민아(21741685100) | * |
dc.date.modifydate | 20240419142141 | * |